全球干癣性关节炎治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计干癣性关节炎治疗市场规模将从 2025 年的 210.6 亿美元增长到 2034 年的 436.3 亿美元，2026 年至 2034 年的复合年增长率为 8.43%。

受自体免疫疾病盛行率上升以及人们对早期诊断和治疗意识提升的推动，全球干癣性关节炎治疗市场正稳步增长。干癣性关节炎常与干癣相关，需要长期使用生物製药、缓解疾病抗风湿药（DMARDs）和标靶治疗。患者群体的扩大和诊断能力的提高是推动市场成长的重要因素。

关键成长要素包括生物製药和标靶分子疗法的进步，这些疗法具有更优的疗效和安全性。医疗保健支出的增加、报销机制的完善以及患者支持计划的实施，正在加速这些疗法的普及。透过临床试验和研究倡议持续关注新型免疫调节疗法，进一步加剧了竞争格局。

未来，个人化医疗方法和生物相似药的引入有望提高治疗的成本效益和可近性。整合用于疾病监测和病人参与的数位化健康工具也将有助于治疗的连续性。免疫疗法的持续创新有望维持干癣性关节炎治疗市场的强劲成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球干癣性关节炎治疗市场：依药物类别划分

• 市场分析、洞察与预测
• TNF抑制剂
• 白细胞介素抑制剂
• PDE4抑制剂
• 其他的

第五章 全球干癣性关节炎治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 肠外
• 外用

第六章 全球干癣性关节炎治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球干癣性关节炎治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AbbVie Inc
  • Janssen Pharmaceutical NV
  • Novartis AG
  • Amgen Inc
  • Celgene Corporation
  • Eli Lilly And Company
  • Bristol Myers Squibb
  • UCB SA
  • Pfizer Inc
  • Sanofi

The Psoriatic Arthritis Therapeutics Market size is expected to reach USD 43.63 Billion in 2034 from USD 21.06 Billion (2025) growing at a CAGR of 8.43% during 2026-2034.

The Global Psoriatic Arthritis Therapeutics Market is growing steadily due to the increasing prevalence of autoimmune disorders and rising awareness about early diagnosis and treatment. Psoriatic arthritis, often associated with psoriasis, requires long-term management using biologics, disease-modifying antirheumatic drugs (DMARDs), and targeted therapies. Expanding patient pools and improved diagnostic capabilities are contributing significantly to market growth.

Key drivers include advancements in biologic drugs and targeted small molecules that offer better efficacy and safety profiles. Increased healthcare spending, improved reimbursement frameworks, and patient support programs are encouraging treatment adoption. Ongoing clinical trials and research initiatives focused on novel immunomodulatory therapies are further strengthening the competitive landscape.

In the future, the market is expected to witness the introduction of personalized medicine approaches and biosimilar products, improving affordability and accessibility. The growing integration of digital health tools for disease monitoring and patient engagement will also support treatment adherence. Continuous innovation in immunotherapy is likely to sustain strong growth in the psoriatic arthritis therapeutics market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• TNF Inhibitors
• Interleukin Inhibitors
• PDE4 Inhibitors
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, Janssen Pharmaceutical NV, Novartis AG, Amgen Inc, Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, UCB SA, Pfizer Inc, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. TNF Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Interleukin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. PDE4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 Janssen Pharmaceutical NV
  • 9.2.3 Novartis AG
  • 9.2.4 Amgen Inc
  • 9.2.5 Celgene Corporation
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 Bristol Myers Squibb
  • 9.2.8 UCB S.A
  • 9.2.9 Pfizer Inc
  • 9.2.10 Sanofi